Last reviewed · How we verify
Amitriptyline plus Fluoxitine
This combination increases serotonin availability in the brain through dual mechanisms: amitriptyline blocks serotonin and norepinephrine reuptake, while fluoxetine selectively inhibits serotonin reuptake.
This combination increases serotonin availability in the brain through dual mechanisms: amitriptyline blocks serotonin and norepinephrine reuptake, while fluoxetine selectively inhibits serotonin reuptake. Used for Depression (off-label or investigational combination), Anxiety disorders (off-label or investigational combination).
At a glance
| Generic name | Amitriptyline plus Fluoxitine |
|---|---|
| Also known as | elavil plus prozac |
| Sponsor | Tufts Medical Center |
| Drug class | Antidepressant combination (tricyclic antidepressant + SSRI) |
| Target | Serotonin transporter (SERT), norepinephrine transporter (NET) |
| Modality | Small molecule |
| Therapeutic area | Psychiatry/Mental Health |
| Phase | FDA-approved |
Mechanism of action
Amitriptyline is a tricyclic antidepressant that inhibits reuptake of both serotonin and norepinephrine at the neuronal synapse. Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) that specifically blocks serotonin reuptake. Together, they create a synergistic increase in synaptic serotonin concentration, potentially enhancing antidepressant and anxiolytic effects. However, this combination is not standard clinical practice and carries increased risk of serotonin syndrome.
Approved indications
- Depression (off-label or investigational combination)
- Anxiety disorders (off-label or investigational combination)
Common side effects
- Serotonin syndrome
- Dry mouth
- Sedation
- Nausea
- Dizziness
- Tremor
- Headache
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Amitriptyline plus Fluoxitine CI brief — competitive landscape report
- Amitriptyline plus Fluoxitine updates RSS · CI watch RSS
- Tufts Medical Center portfolio CI